Abiomed closed at $319.78 in the latest trading session, marking a -0.31% move from the prior day. This move lagged the S&P 500's daily gain of 0.22%. At the same time, the Dow added 0.49%, and the tech-heavy Nasdaq lost 0.15%.
Heading into today, shares of the maker of heart devices had lost 17.03% over the past month, lagging the Medical sector's gain of 0.16% and the S&P 500's loss of 0.57% in that time.
ABMD will be looking to display strength as it nears its next earnings release, which is expected to be February 7, 2019. In that report, analysts expect ABMD to post earnings of $0.94 per share. This would mark year-over-year growth of 34.29%. Meanwhile, our latest consensus estimate is calling for revenue of $195.18 million, up 26.72% from the prior-year quarter.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $4.97 per share and revenue of $770.45 million. These totals would mark changes of +102.86% and +29.76%, respectively, from last year.
Investors should also note any recent changes to analyst estimates for ABMD. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 2.93% higher within the past month. ABMD currently has a Zacks Rank of #2 (Buy).
In terms of valuation, ABMD is currently trading at a Forward P/E ratio of 64.54. This represents a premium compared to its industry's average Forward P/E of 32.61.
Also, we should mention that ABMD has a PEG ratio of 1.88. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Instruments was holding an average PEG ratio of 2.54 at yesterday's closing price.
The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 80, which puts it in the top 31% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow ABMD in the coming trading sessions, be sure to utilize Zacks.com.
Image: Bigstock
Abiomed (ABMD) Stock Sinks As Market Gains: What You Should Know
Abiomed closed at $319.78 in the latest trading session, marking a -0.31% move from the prior day. This move lagged the S&P 500's daily gain of 0.22%. At the same time, the Dow added 0.49%, and the tech-heavy Nasdaq lost 0.15%.
Heading into today, shares of the maker of heart devices had lost 17.03% over the past month, lagging the Medical sector's gain of 0.16% and the S&P 500's loss of 0.57% in that time.
ABMD will be looking to display strength as it nears its next earnings release, which is expected to be February 7, 2019. In that report, analysts expect ABMD to post earnings of $0.94 per share. This would mark year-over-year growth of 34.29%. Meanwhile, our latest consensus estimate is calling for revenue of $195.18 million, up 26.72% from the prior-year quarter.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $4.97 per share and revenue of $770.45 million. These totals would mark changes of +102.86% and +29.76%, respectively, from last year.
Investors should also note any recent changes to analyst estimates for ABMD. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 2.93% higher within the past month. ABMD currently has a Zacks Rank of #2 (Buy).
In terms of valuation, ABMD is currently trading at a Forward P/E ratio of 64.54. This represents a premium compared to its industry's average Forward P/E of 32.61.
Also, we should mention that ABMD has a PEG ratio of 1.88. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Instruments was holding an average PEG ratio of 2.54 at yesterday's closing price.
The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 80, which puts it in the top 31% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow ABMD in the coming trading sessions, be sure to utilize Zacks.com.